Pfizer expects Covid vaccine demand for years

Pfizer expects Covid vaccine demand for years
In the first three months of 2021, the vaccine generated revenues of $3.5bn (£2.5bn) as governments scrambled to try to contain the pandemic.

Revenue from the treatment is expected to hit $26bn this year - accounting for more than one third of Pfizer s sales.

The forecast is based on already-signed contracts for 1.6 billion vaccine doses to be delivered this year.

Pfizer said it expected to sign more deals this year, and was in supply talks with several countries for 2022 and beyond.

"Based on what we ve seen, we believe that a durable demand for our Covid-19 vaccine - similar to that of the flu vaccines - is a likely outcome," said chief executive Albert Bourla.

The two-shot vaccine was Pfizer s top-selling product in the first quarter.

Expenses and profit from the vaccine are split 50-50 between Pfizer and its German partner BioNTech.

Pfizer and fellow US firm Moderna profit from their vaccines, while AstraZeneca and US giant Johnson & Johnson are supplying theirs at cost price while the pandemic continues.

Pfizer recently signed a contract with the UK to supply 60 million additional doses in 2021.

It is testing the use of a third dose of its vaccine as a booster, and expects the US to give the go-ahead for it to be used in children between 12 and 15 years old during the pandemic.
News Topics :
Similar Articles :
The first Covid 19 vaccination in the United States has taken place, as the country gears up for its largest ever immunisation campaign. An intensive care nurse in Long Island, New...
The UK has been using the AstraZeneca vaccine in its mass immunisation programme for weeks now, and public health officials say it is safe and provides high levels of protection ....
Johnson & Johnson on Tuesday said it expected to report eagerly awaited data on its COVID 19 vaccine early next week, and that it would be able to meet the delivery...
There have been more than 55 million cases of the virus confirmed around the world and more than 1.3 million deaths. Many hopes are pinned on a vaccine as a...
Pfizer Inc. laid out a plan to turn its COVID 19 vaccine into a long term business, clinching supply agreements that will yield $26 billion all figures U.S. in sales this year...